Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + cisplatin with anlotinib, toripalimab, and stereotactic body radiotherapy for metastatic nasopharyngeal carcinoma
ChiCTR2100045190Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Jul 2021
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of gemcitabine, cisplatin, anlotinib and toripalimab in nasopharyngeal carcinoma (NPC), sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoint: Objective response rate. Started Jul 2021; status: recruiting.
02
Drugs
gemcitabinecisplatinanlotinibtoripalimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2100045190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045190.